title: [Visceral leishmaniasis associated with human immunodeficiency virus infection].
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain. vpintado@hrc.insalud.es
authors.forename: V
authors.initials: V
authors.lastname: Pintado
authors.forename: R
authors.initials: R
authors.lastname: López-Vélez
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology / Q000469:parasitology; D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001706:Biopsy; D001856:Bone Marrow Examination; D004866:Equipment Contamination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D015994:Incidence; D018314:Leishmania infantum / Q000276:immunology / Q000502:physiology; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D008297:Male; D019083:Mediterranean Region / Q000453:epidemiology; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D016485:Needle Sharing; D009942:Organometallic Compounds / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D013154:Spleen / Q000469:parasitology / Q000473:pathology; D015819:Substance Abuse, Intravenous / Q000150:complications
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B